OSAKA -- Matsushita Electric Industrial Co. and U.S. venture business Tensor Biosciences have signed an agreement to jointly develop and commercialize Brain-on-a-Chip drug discovery technology, the two companies said Tuesday.
The five-year agreement calls for combining advanced Matsushita instruments that enable the real-time study of activity patterns in living brain tissue with Tensor's realistic brain models and associated drug tests.
Specifically, the joint work will focus on Tensor's Brain-on-a-Chip platform of testing assays centered around Matsushita's MED64 System, a multielectrode neurophysiology instrument for use in neurobiological research.
The two companies will test drugs for the treatment of neurological diseases such as depression and epilepsy.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.